Drug intelligence / Profile preview

QiXian decoction

Development stage: Unknown
Lead developer: Shanghai University of Traditional Chinese Medicine
Administration: Oral

Overview

QiXian decoction is a Traditional Chinese Medicine (TCM) herbal formula developed by the Shanghai University of Traditional Chinese Medicine Affiliated Putuo Hospital. It is primarily investigated for the treatment of asthma, with clinical trials focusing on its ability to improve asthma control, reduce the frequency and severity of exacerbations, and decrease the required dosage of inhaled corticosteroids. As a TCM decoction, it is composed of multiple herbal ingredients that are thought to work synergistically to provide anti-inflammatory and immunomodulatory effects on the respiratory system.

Other names: Qi Xian decoctionQi Xian Fang

Targets

ERKIL-6R (Interleukin-6 receptor subunit alpha)JNK (Mitogen-activated protein kinase kinase kinase family)CDH1 (Cadherin-1)

Beyond the preview

Go deeper on QiXian decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QiXian decoction.

Explore the full profile